Marshall Wace North America’s Theravance Biopharma TBPH Stock Holding History

Marshall Wace North America’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,215	Closed	-$31K	–	1887
2018 Q4	$31K	Buy	+1,215	New	+$32.8K	﹤0.01%	1361
2017 Q3	–	Sell	-221,180	Closed	-$8.85M	–	1493
2017 Q2	$8.85M	Sell	221,180 -369,693	-63%	-$14.2M	0.06%	353
2017 Q1	$21.9M	Buy	+590,873	New	+$18.9M	0.17%	162

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace North America's TBPH Position: Q1 2019 in Review

Marshall Wace North America sold out of Theravance Biopharma (TBPH) in Q1 2019, closing a stake of 1,215 shares — an estimated $31K sold.

Marshall Wace North America first reported a position in TBPH in Q1 2017 and held it in 3 quarters. The position peaked at $21.9M in Q1 2017. 104 funds tracked by Wall St. Rank hold TBPH as of Q1 2019.

Marshall Wace North America reported no remaining Theravance Biopharma position as of Q1 2019 after selling out during the quarter.
Marshall Wace North America sold 1,215 Theravance Biopharma shares in Q1 2019, an estimated $31K.
Marshall Wace North America first reported a position in Theravance Biopharma in Q1 2017 and held it in 3 quarters.
Marshall Wace North America's Theravance Biopharma position peaked at $21.9M in Q1 2017.
104 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.